Boston Scientific to enhance urology portfolio by acquiring Axonics in $3.7bn deal

Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement to acquire Axonics, Inc. (Nasdaq: AXNX), a leading medical technology company specializing in urinary ... Read More